期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

齐拉西酮和艾司西酞普兰治疗重性抑郁障碍观察 被引量：4

原文传递
导出
摘要 目的探讨齐拉西酮联合艾司西酞普兰治疗重性抑郁障碍的疗效。方法选取2012年1至2014年2月确诊为DSM-ⅳ-TR的重性抑郁患者92例,按照数字随机发分为观察组46例和对照组46例,对照组仅给予艾司西酞普兰,观察组在对照组基础上加用齐拉西酮。分别比较两组治疗前后的汉密尔顿抑郁量表评(HAMD)分及副反应量表(TESS)评分。结果观察组有效率高达73.91%,明显高于对照组的60.87%,差异有统计学意义(P<0.01)。观察组在治疗后4周、6周和8周的HAMD评分明显低于同期对照组(P<0.05),但两组治疗后2周、4周、6周和8周的TESS评分比较差异无统计学意义(P>0.05)。结论齐拉西酮联合艾司西酞普兰治疗重性抑郁障碍效果好,不良反应少,安全性高,值得进一步推广。
作者 张子迪
机构地区 天津市安定医院
出处 《医药论坛杂志》 2014年第12期140-141,共2页 Journal of Medical Forum
关键词 齐拉西酮 艾司西酞普兰 重性抑郁障碍 疗效
分类号 R971 [医药卫生—药品]
  • 相关文献

参考文献8

二级参考文献69

  • 1汪春运.齐哌西酮的精神科应用[J].国外医学（精神病学分册）,2005,32(1):40-43. 被引量：90
  • 2甘景梨,金卫东,钱敏才,胡纪明,冯斌.文拉法辛与SSRI治疗抑郁症痊愈率的循证医学研究[J].山东精神医学,2006,19(1):6-8. 被引量：18
  • 3韩明杰,高桂芳.齐拉西酮与氯氮平治疗晚发精神分裂症的疗效比较[J].四川精神卫生,2007,20(3):162-163. 被引量：8
  • 4Levinson DF. The genetic of depression: a review. Biol Psychiatry,2006,60:84.
  • 5Haenisch B, Herms S, Mattheisen M, et al. Genome-wide associationdata provide further support for an association between 5-HTTT>PR andmajor depressive disorder. J Affect Disord ,2013,146 :438440.
  • 6Zhang K,Xu Q ,Xu Y , et al. The combined effects of the 5-HTHPRand 5-HTRIA genes modulates the relationship between negative lifeevents and major depressive disorder in a Chinese populalion. J AffectDisord,2009,114 ;224-231.
  • 7Lopez de Lara C,Dumais A,Rouleau G, el al. S Tin2 variant and iarn-ily history of suicide as significant predictors of suicide coniplelion inmajor depression. Biol Psychiatry ,2006,59 : 114-120.
  • 8Sun N,Xu Y, Wang Y, el al. The combined ellect of norepinephrinetransporter gene and negative life events in major depression of (Chi-nese Han population. J Neural Transm ,2008 ,115 : 1681 -1686.
  • 9Baffa A, Hohoff C, Baune BT, et al. Norepinephrine and serotonintransporter genes : impacl on treatment response in depression. Neuro-psychobiology ,2010,62 : 121 -131.
  • 10Lotrich FE, Pollock BG, Ferrell RE. Polymorphism of the serotonintransporter:implications tor the use of selective serotonin reuptake in-hibitors. Am J Pharmacogenomies,2001 ,1 : 153-64.

共引文献43

同被引文献19

  • 1无.良性阵发性位置性眩晕的诊断依据和疗效评估(2006年,贵阳)[J].中华耳鼻咽喉头颈外科杂志,2007,42(3):163-164. 被引量：784
  • 2Shefer S,Gordon CR, Avrabam K B,et al. Progressive vestibular mutation leads to elevated anxietyFJ~. Brain Res,2010,13(4) :157-164.
  • 3Prim-Espada MP, De DiegceSastre JI, P~rez-Ferndndez E. Metwanalysis on the efficacy of Epley's manoeuvre in be nign parox-ysmal positional vertigo[J]. Neurologia, 2010, 25(5) :295-299.
  • 4Lee SH,Kim JS. Benign paroxysmal positional vertigo {-J~. J CIin Neurol,2010,6 (2) : 539-541.
  • 5Li H, Li T, Li G, et al. Citalopram and escitalopram in the treatment of major depressive disorder: a pooled analysis of 3 clinical trials2J~. Ann Clin Psychiatry,2014,26(4) ~281-287.
  • 6Beaune S, Callebert J, Baud FJ, et ai. Mechanisms of high-dose eitalopram induced death in a rat model[J]. Toxicology, 2012, 302 (2/3) : 248-254.
  • 7Oransay K, Hocaoglu N, Buyukdeligoz M, et al. The role of adenosine receptors and endogenous adenosine in citalopram- induced cardiovascular toxicity[J]. Indian J Pharmacol, 2014,46 (4) :378-385.
  • 8Ji Y, Schaid DJ, Desta ZJ, et al. Citalopram and escitalopram plasma drug and metabolite concentrations: genome wide associations[J]. Br J Ciin Pharmaco|, 2014,78(2) : 373-383.
  • 9Chang M, Tyhring G, Dahl ML, et al. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis[J]. Clin Pharmacokinet, 2014,53(9) :801-811.
  • 10Greiner C, Hiemke C, Bader W, et al. Determination of citalopram and escitalopram together with their active main metabolites desmethyl (es-)citalopram in human serum by column-switching high performance liquid chromatography (HPLC) and spectrophotometric detection[J]. J Chromatogr B Analyt Technol Biomed Life Sci,2007,848(2) :391-394.

引证文献4

二级引证文献17

医药论坛杂志
2014年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部